Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
33161592
PubMed Central
PMC8247412
DOI
10.1111/bjh.17210
Knihovny.cz E-resources
- Keywords
- ALL, AML, acute leukaemia, flow cytometry, immunophenotyping, myeloperoxidase,
- MeSH
- Acute Disease MeSH
- Immunophenotyping standards MeSH
- Leukemia * diagnosis enzymology immunology MeSH
- Humans MeSH
- Neoplasm Proteins * blood immunology MeSH
- Peroxidase * blood immunology MeSH
- Flow Cytometry standards MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- MPO protein, human MeSH Browser
- Neoplasm Proteins * MeSH
- Peroxidase * MeSH
Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.
Cancer Research Center Salamanca Spain
Centro de Investigaciόn Biomédicaen Red de Cáncer Instituto Carlos 3 Madrid Spain
Department of Hematology Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands
Department of Immunology Leiden University Medical Center Leiden The Netherlands
Department of Pediatric Hematology and Oncology Zabrze Medical University of Silesia Katowice Poland
Dutch Childhood Oncology Group Utrecht the Netherlands
Institute for Laboratory Medicine Kantonsspital Aarau AG Aarau Switzerland
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
See more in PubMed
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51. PubMed
Olsen RJ, Chang CC, Herrick JL, Zu Y, Ehsan A. Acute leukemia immunohistochemistry: a systematic diagnostic approach. Arch Pathol Lab Med. 2008;132:462–75. PubMed
Kappelmayer J, Gratama JW, Karászi E, Menéndez P, Ciudad J, Rivas R, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods. 2000;242:53–65. PubMed
Ahuja A, Tyagi S, Seth T, Pati HP, Gahlot G, Tripathi P, et al. Comparison of immunohistochemistry, cytochemistry, and flow cytometry in AML for myeloperoxidase detection. Indian J Hematol Blood Transfus. 2018;34:233–9. PubMed PMC
Reilly JT, Barnett D. UK NEQAS for leucocyte immunophenotyping: the first 10 years. J Clin Pathol. 2001;54:508–11. PubMed PMC
Kalina T, Flores‐Montero J, van der Velden VHJ, Martin‐Ayuso M, Böttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010. PubMed PMC
van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores‐Montero J, et al. EuroFlow antibody panels for standardized n‐dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–75. PubMed PMC
Oberley MJ, Li S, Orgel E, Phei Wee C, Hagiya A, O’Gorman MR. Clinical significance of isolated myeloperoxidase expression in pediatric B‐lymphoblastic leukemia. Am J Clin Pathol. 2017;147:374–81. PubMed
Savaşan S, Buck S, Gadgeel M, Gabali A. Flow cytometric false myeloperoxidase‐positive childhood B‐lineage acute lymphoblastic leukemia. Cytometry. 2018;94:477–83. PubMed
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. Cytometry. 2019;96:183–94. PubMed
Guy J, Antony‐Debré I, Benayoun E, Arnoux I, Fossat C, Le Garff‐Tavernier M, et al. Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. Br J Haematol. 2013;161:551–5. PubMed
van den Ancker W, Westers TM, de Leeuw DC, van der Veeken YF, Loonen A, van Beckhoven E, et al. A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytometry. 2013;84:114–8. PubMed
Saravanan L, Juneja S. Immunohistochemistry is a more sensitive marker for the detection of myeloperoxidase in acute myeloid leukemia compared with flow cytometry and cytochemistry. Int J Lab Hematol. 2010;32:e132–6. PubMed
Manivannan P, Puri V, Somasundaram V, Purohit A, Sharma RK, Dabas M, et al. Can threshold for MPO by flow cytometry be reduced in classifying acute leukaemia? A comparison of flow cytometric and cytochemical myeloperoxidase using different flow cytometric cut‐offs. Hematology. 2015;20:455–61. PubMed
Lee H, Kim Y, Kim YJ, Han K. An unusual case of myeloperoxidase‐positive acute megakaryoblastic leukemia. Ann Lab Med. 2015;35:466–8. PubMed PMC
